 Thiazolidinediones
"Thiazolidinediones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).
| Descriptor ID |
D045162
|
| MeSH Number(s) |
D02.886.675.933 D03.383.129.708.933
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiazolidinediones".
Below are MeSH descriptors whose meaning is more specific than "Thiazolidinediones".
This graph shows the total number of publications written about "Thiazolidinediones" by people in this website by year, and whether "Thiazolidinediones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 0 | 2 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2011 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Thiazolidinediones" by people in Profiles.
-
Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, Muthupillai R, Chan L, Bajaj M. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia. 2011 Dec; 54(12):3093-100.
-
Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring). 2011 Dec; 19(12):2310-5.
-
Artunc F, Sandulache D, Nasir O, Boini KM, Friedrich B, Beier N, Dicks E, Pötzsch S, Klingel K, Amann K, Blazer-Yost BL, Scholz W, Risler T, Kuhl D, Lang F. Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPARgamma agonist pioglitazone. Pflugers Arch. 2008 May; 456(2):425-36.
-
Trivedi M, Lokhandwala MF. Rosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats. Am J Physiol Renal Physiol. 2005 Aug; 289(2):F298-304.
-
Trivedi M, Marwaha A, Lokhandwala M. Rosiglitazone restores G-protein coupling, recruitment, and function of renal dopamine D1A receptor in obese Zucker rats. Hypertension. 2004 Feb; 43(2):376-82.
-
Umrani DN, Banday AA, Hussain T, Lokhandwala MF. Rosiglitazone treatment restores renal dopamine receptor function in obese Zucker rats. Hypertension. 2002 Dec; 40(6):880-5.
-
Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR, Ogilvie KM, Liu S, Kauffman RF. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes. 2002 Apr; 51(4):1083-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|